RESPONSE-ADAPTED TREATMENT WITH RITUXIMAB/BENDAMUSTINE/MITOXANTRONE/DEXAMETHASONE AND MAINTENANCE THERAPY WITH RITUXIMAB IN PATIENTS WITH FOLLICULAR LYMPHOMA IN RELAPSE OR REFRACTORY TO FIRST-LINE TREATMENT WITH IMMUNOCHEMOTHERAPY. RBMDGELTAMO08

被引:0
|
作者
Francisco Javier, Penalver Parraga [1 ]
Jose Antonio, Marquez Navarro [2 ]
Nieto Soledad, Duran [3 ]
Castellano Pilar, Giraldo [4 ]
Sanz Carlos, Montalban [5 ]
Maria Jose, Ramirez Sanchez [6 ]
Juan Manuel, Sancho Cia [7 ]
Maria Jose, Terol Castera [8 ]
Francisco Javier, Capote Huelva [9 ]
Garcia Antonio, Gutierrez [10 ]
Gonzalez Blanca, Sanchez [11 ]
Silvestre Antonio, Salar [11 ]
Albendea Miguel, Canales [12 ]
Maria Dolores, Caballero Barrigon
机构
[1] Hosp Univ Fdn Alcorcon, Madrid, Spain
[2] Hosp Basurto, Bilbao, Spain
[3] Complejo Hosp Jaen, Jaen, Spain
[4] Hosp Univ Miguel Servet, Zaragoza, Spain
[5] Hosp Univ Ramon & Cajal, Madrid, Spain
[6] Hosp Especialidades Jerez de la Frontera, Cadiz, Spain
[7] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain
[8] Hosp Clin Univ Valencia, Valencia, Spain
[9] Hosp Puerta del Mar, Cadiz, Spain
[10] Hosp Univ Son Dureta, Palma De Mallorca, Spain
[11] Hosp del Mar, Barcelona, Spain
[12] Hosp Univ La Paz, Madrid, Spain
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
CO-011
引用
收藏
页码:9 / 9
页数:1
相关论文
共 50 条
  • [1] Response-Adapted Treatment with Rituximab/Bendamustine/Mitoxantrone/Dexamethasone and Maintenance Therapy with Rituximab in Patients with Follicular Lymphoma in Relapse or Refractory to First-Line Treatment with Immunochemotherapy. RBMDGELTAMO08 Trial
    Parraga, Francisco Javier Penalver
    Navarro, Jose Antonio Marquez
    Nieto, Soledad Duran
    Castellano, Pilar Giraldo
    Sanz, Carlos Montalban
    Sanchez, Maria Jose Ramirez
    Cia, Juan-Manuel Sancho
    Castera, Maria Jose Terol
    Huelva, Francisco Javier Capote
    Garcia, Antonio Gutierrez
    Gonzalez, Blanca Sanchez
    Silvestre, Antonio Salar
    Albendea, Miguel Canales
    Barrigon, Maria Dolores Caballero
    BLOOD, 2016, 128 (22)
  • [2] Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial
    Penalver, Francisco-Javier
    Marquez, Jose-Antonio
    Duran, Soledad
    Giraldo, Pilar
    Martin, Alejandro
    Montalban, Carlos
    Sancho, Juan-Manuel
    Ramirez, Maria-Jose
    Terol, Maria-Jose
    Capote, Francisco-Javier
    Gutierrez, Antonio
    Sanchez, Blanca
    Lopez, Andres
    Salar, Antonio
    Rodriguez-Caravaca, Gil
    Canales, Miguel
    Caballero, Maria-Dolores
    Bello Lopez, Jose Luis
    Carbonell, Felix
    Ferrer Bordas, Secundino
    Font Lopez, Patricia
    Perez Persona, Ernesto
    Lopez Guillermo, Armando
    Hernandez Martin, Roberto
    Ramon Mayans, Jose
    Palomera, Luis
    Perez Ceballos, Elena
    Queizan Hernandez, Jose Antonio
    Riaza Grau, Rosalia
    de la Cruz, Fatima
    Sanchez Salinas, Andres
    CANCER MEDICINE, 2019, 8 (16): : 6955 - 6966
  • [3] Rituximab, Bendamustine, Mitoxantrone, Dexamethasone (R-BMD) in Patients with Follicular Lymphoma in Relapse or Refractory to First-Line Treatment with Immunochemotherapy. R-BMD Geltamo 08 Trial
    Javier Penalver, Francisco
    Antonio Marquez, Jose
    Duran, Soledad
    Giraldo, Pilar
    Montalban, Carlos
    Jose Ramirez, Marya
    Manuel Sancho, Juan
    Jose Terol, Maria
    Javier Capote, Francisco
    Gutierrez, Antonio
    Sanchez, Blanca
    Canales, Miguel
    Dolores Caballero, Maria
    BLOOD, 2012, 120 (21)
  • [4] FIRST LINE TREATMENT WITH BENDAMUSTINE-RITUXIMAB IN PATIENTS WITH FOLLICULAR LYMPHOMA
    Buenasmananas Cervantes, D.
    Calle Primo, C.
    Nebro Luque, M. dM
    Hernandez Ruiz, B.
    HAEMATOLOGICA, 2015, 100 : 266 - 266
  • [5] High Risk of Transformation and Secondary Malignancies in Follicular Lymphoma Patients Treated With First-line Bendamustine Rituximab and Rituximab Maintenance
    Rangel-Patino, Juan
    Kridel, Robert
    Kuruvilla, John
    Prica, Anca
    Kukreti, Vishal
    Bhella, Sita
    Delabie, Jan
    Vijenthira, Abi
    Crump, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S503 - S503
  • [6] Assessment of Maintenance Rituximab after First-Line Bendamustine-Rituximab in Patients with Follicular Lymphoma: An Analysis from the BRIGHT Trial
    Kahl, Brad S.
    Burke, John M.
    van der Jagt, Richard
    Chang, Julie
    Wood, Peter
    Hawkins, Tim
    MacDonald, David
    Trotman, Judith
    Simpson, David
    Kolibaba, Kathryn S.
    Issa, Samar
    Hallman, Doreen
    Chen, Ling
    Flinn, Ian W.
    BLOOD, 2017, 130
  • [7] A randomized trial of fludarabine and mitoxantrone plus rituximab versus CHOP plus rituximab as first-line treatment in patients with follicular lymphoma.
    Zinzani, PL
    BLOOD, 2001, 98 (11) : 842A - 842A
  • [8] Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain
    Eliazar Sabater
    Armando López-Guillermo
    Antonio Rueda
    Antonio Salar
    Itziar Oyagüez
    Juan Manuel Collar
    Applied Health Economics and Health Policy, 2016, 14 : 465 - 477
  • [9] Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain
    Sabater, Eliazar
    Lopez-Guillermo, Armando
    Rueda, Antonio
    Salar, Antonio
    Oyaguez, Itziar
    Manuel Collar, Juan
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2016, 14 (04) : 465 - 477
  • [10] A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma
    Gressin, Remy
    Daguindau, Nicolas
    Tempescul, Adrian
    Moreau, Anne
    Carras, Sylvain
    Tchernonog, Emmanuelle
    Schmitt, Anna
    Houot, Roch
    Dartigeas, Caroline
    Pignon, Jean Michel
    Corm, Selim
    Banos, Anne
    Mounier, Christiane
    Dupuis, Jehan
    Macro, Margaret
    Fleury, Joel
    Jardin, Fabrice
    Sarkozy, Clementine
    Damaj, Ghandi
    Feugier, Pierre
    Fornecker, Luc Matthieu
    Chabrot, Cecile
    Dorvaux, Veronique
    Bouadallah, Krimo
    Amorin, Sandy
    Garidi, Reda
    Voillat, Laurent
    Joly, Bertrand
    Celigny, Philippe Solal
    Morineau, Nadine
    Moles, Marie Pierre
    Zerazhi, Hacene
    Fontan, Jean
    Arkam, Yazid
    Alexis, Magda
    Delwail, Vincent
    Vilque, Jean Pierre
    Ysebaert, Loic
    Le Gouill, Steven
    Callanan, Mary B.
    HAEMATOLOGICA, 2019, 104 (01) : 138 - 146